![]() |
市場調查報告書
商品編碼
2041842
服務實驗室市場預測—按服務類型、應用和地區分類的全球分析—2034年Service Laboratory Market Forecasts to 2034 - Global Analysis By Service Type, By Application and By Geography |
||||||
全球服務實驗室市場預計到 2026 年將達到 2,484.1 億美元,在預測期內以 3.1% 的複合年成長率成長,到 2034 年將達到 3,171.4 億美元。
服務實驗室是指利用專用設備在醫療環境中監測、測量和檢測電離輻射水平的工作。這些設備透過追蹤輻射暴露情況並評估治療(例如X光、 電腦斷層掃描和放射治療)期間的劑量,確保安全,從而保護患者和醫護人員免受過度輻射。
根據美國疾病管制與預防中心(CDC)統計,每年進行140億次臨床檢測。據估計,70%的醫療決策都基於臨床檢測結果。
診斷測試需求不斷成長
隨著人們對預防醫學和疾病早期檢測的重視程度不斷提高,對精準、先進的診斷檢測的需求也日益成長。人口老化、慢性病發病率上升以及診斷設備技術的進步等因素,都促成了這項需求的激增。因此,服務實驗室收到的診斷檢測項目種類也隨之增加,滿足了醫療保健及相關行業對精準、快速、全面的診斷服務日益成長的需求,從而推動了市場成長。
高昂的營運成本和資本投資成本
由於需要最尖端科技、專用設備、熟練人員以及嚴格遵守監管標準,營運成本居高不下。此外,建立和維護檢查室所需的初始投資也推高了資本支出成本。這些高昂的營運和資本支出成本對進入市場的中小型企業構成挑戰,可能限制其競爭力以及對創新進行投資的能力。
個性化醫療的興起
個人化醫療依賴精準的診斷檢測和基於個人基因組成、生活方式和特定健康特徵的個人化治療。這一趨勢推動了對先進檢測服務的需求,包括基因檢測、生物標記分析和分子診斷,從而催生了對專業檢查室的需求。服務於個人化醫療的檢查室能夠透過提供全面的檢測服務,幫助醫療機構提供更有效、更有針對性的治療,從而推動個人化醫療的發展,並拓展服務檢查室市場的成長機會。
持續的技術進步
快速的技術進步可能導致現有設備和調查方法過時,從而需要頻繁升級和投資新技術。這種持續的適應和創新需求給檢查室帶來了財務壓力,使其難以保持競爭力。此外,快速的變化速度也會造成舊有系統系統之間的差距,影響偵測程序的標準化和一致性。服務提供者在採用新技術的同時,也可能需要兼顧服務的連續性和可靠性,這同樣是一項挑戰。
新冠疫情對服務實驗室市場產生了重大影響,導致診斷檢測服務需求激增。全球各地的實驗室都面臨病毒檢測需求的激增,引發了營運挑戰、供應鏈中斷和勞動力短缺等問題。此外,疫情加速了研發活動,凸顯了服務實驗室在疾病診斷、治療方法研發和公共衛生應對策略中的重要角色。
在預測期內,常規檢測部分預計將成為最大的部分。
在預測期內,常規檢測領域預計將成為最大的細分市場。這主要是由於其在各行各業和日常營運中的廣泛應用。製藥、食品飲料和製造業等行業高度依賴常規檢測來進行品質保證和合規性審查。因此,對常規和標準化檢測程序的持續需求預計將使常規檢測領域在預測期內成為整體檢測服務市場的主導和最大貢獻者。
預計在預測期內,臨床實驗室領域將呈現最高的複合年成長率。
預計在預測期內,臨床實驗室領域將實現最高成長率,這主要得益於醫療保健支出增加、預防醫學意識增強以及慢性病發病率上升,這些因素共同推動了對臨床實驗室服務的需求。此外,診斷技術的進步,以及對疾病早期檢測和個人化醫療的重視,也進一步提升了對綜合臨床實驗室檢測的需求。這些因素共同推動了臨床實驗室領域的擴張,並表明其在醫療產業中具有強勁的成長潛力。
北美憑藉其先進的醫療保健基礎設施佔據市場主導地位,這促進了對診斷和檢測服務的強勁需求。此外,蓬勃發展的製藥和生技產業也推動了對專業檢查室分析的需求。同時,嚴格的監管標準要求進行全面的檢測,進一步提升了對檢查室服務的需求。主要產業參與者的存在、技術的進步以及對研發的高度重視,共同促成了北美在檢查室服務業佔據最大市場佔有率的地位。
在亞太地區,快速的工業化、技術進步以及醫療保健和製藥等領域研發活動的增加預計將推動市場顯著成長。此外,嚴格的品質標準、快速成長的人口以及產業外包趨勢也促進了對外包檢測服務的需求。該地區的經濟擴張和對創新的重視正使其成為服務檢查室的重要中心,從而推動市場實現顯著成長。
According to Stratistics MRC, the Global Service Laboratory Market is accounted for $248.41 billion in 2026 and is expected to reach $317.14 billion by 2034 growing at a CAGR of 3.1% during the forecast period. Service Laboratory involves the use of specialised devices to monitor measure and detect ionising radiation levels in medical settings. These instruments ensure safety by tracking radiation exposure, assessing dosage during treatments like X-rays, CT scans or radiation therapy and safeguarding both patients and healthcare professionals from potential overexposure to radiation.
According to the Centers for Disease Control, 14 billion lab tests are conducted annually. It is estimated 70% of medical decisions are based on lab test results.
Increasing demand for diagnostic testing
With a growing focus on preventive healthcare and early disease detection, there's an increased need for accurate and advanced diagnostic tests. Factors like an aging population, escalating incidences of chronic diseases and technological advancements in diagnostic tools contribute to this demand surge. Consequently, service laboratories experience heightened requests for a diverse range of diagnostic tests, driving market growth as they cater to the escalating need for precise, timely and comprehensive diagnostic services across healthcare and related industries.
High operational and capital costs
The need for cutting-edge technology, specialised equipment, skilled personnel and stringent compliance with regulatory standards leads to substantial operational expenses. Additionally, the initial investment in setting up and maintaining state-of-the-art laboratories adds to the capital costs. These high operational and capital expenses can pose challenges for smaller players entering the market, limiting their ability to compete and invest in innovation.
Rise in personalized medicine
Personalised medicine relies on precise diagnostic tests and tailored treatments based on an individual's genetic makeup, lifestyle and specific health characteristics. This trend fuels the demand for advanced testing services, including genetic testing, biomarker analysis and molecular diagnostics, requiring specialised laboratories. Service laboratories catering to personalised medicine can offer comprehensive testing services, supporting healthcare providers in delivering more effective, targeted treatments, thereby driving the growth of personalised medicine and expanding opportunities within the service laboratory market.
Continuous technological advancements
Rapid technological evolution might render existing equipment or methodologies obsolete, necessitating frequent upgrades or investments in new technology. This constant need for adaptation and innovation places financial pressure on laboratories to stay competitive. Moreover, the rapid pace of change could create a gap between updated and legacy systems, impacting standardisation and consistency in testing procedures and potentially challenging service providers to maintain a balance between adopting new technologies and ensuring continuity and reliability in their services.
The COVID-19 pandemic significantly affected the service laboratory market, triggering increased demand for diagnostic testing services. Laboratories worldwide faced a surge in testing requirements for virus detection, leading to operational challenges, supply chain disruptions and workforce constraints. Additionally, the pandemic accelerated research and development activities, emphasising the importance of service laboratories in disease diagnosis, treatment development and public health response strategies.
The routine testing segment is expected to be the largest during the forecast period
The routine testing segment is anticipated to be the largest during the forecast period, primarily owing to its widespread application across various industries and everyday processes. Industries such as pharmaceuticals, food and beverage and manufacturing heavily rely on routine testing for quality assurance and regulatory compliance. As a result, the consistent demand for regular, standardised testing procedures positions the routine testing segment as the dominant and largest contributor to the broader testing services market during the forecast period.
The clinical testing segment is expected to have the highest CAGR during the forecast period
The clinical testing segment is projected to achieve the highest growth rate during the forecast period owing to increasing healthcare expenditure, growing awareness about preventive healthcare and a rise in chronic diseases, which drive the demand for clinical testing services. Moreover, advancements in diagnostic technologies, coupled with a focus on early disease detection and personalised medicine, propel the need for comprehensive clinical testing. These factors collectively fuel the expansion of the clinical testing segment, indicating robust growth potential in the healthcare industry.
North America is positioned to dominate the market due to the region's advanced healthcare infrastructure, which fosters a high demand for diagnostic and testing services. Additionally, a robust pharmaceutical and biotechnology sector drives the need for specialised laboratory analyses. Moreover, stringent regulatory standards necessitate comprehensive testing, further boosting the demand for service laboratories. The presence of major industry players, technological advancements and a strong emphasis on research and development collectively contribute to North America's largest market share in the service laboratory industry.
The Asia-Pacific region anticipates significant growth in the market due to rapid industrialization, technological advancements and increasing research and development activities across sectors like healthcare and pharmaceuticals. Additionally, stringent quality standards, a burgeoning population and the outsourcing trend in industries fuel the need for outsourced laboratory services. This region's expanding economies and the emphasis on innovation position it as a key hub for service laboratories, fostering substantial market growth.
Key players in the market
Some of the key players in Service Laboratory Market include Abbott Laboratories, ACM Global Laboratories, Agilent Technologies, Beckman Coulter, BioReference Laboratories, Bruker Corporation, Charles River Laboratories, Eurofins Scientific, Genomic Health, Labcorp, NeoGenomics Laboratories, PerkinElmer, Qiagen NV, Quest Diagnostics, Roche Diagnostics, Siemens Healthineers, Sonic Healthcare, SYNLAB International GmbH, Thermo Fisher Scientific and Waters Corporation.
In June 2023, IMCD inaugurated an additional facility close to Philadelphia. To better serve its clients in North America, IMCD announced the relocation and opening of its "IMCD Coatings & Construction Laboratory.
In June 2022, Labcorp, a paramount global life sciences company, announced the expansion of CB Trial Laboratory, the central laboratory shared by Labcorp Drug Development and BML, a top Japanese provider of clinical laboratory testing services, to strengthen its central laboratory presence and drug development capabilities in Japan.